Serum relaxin in systemic sclerosis

Objective. To evaluate serum levels of relaxin (RLX), a hormone with acknowledged antifibrotic activity, in patients with systemic sclerosis (SSc). Methods. We performed a pilot study of 50 outpatients with SSc and 50 healthy subjects. Serum RLX was measured using the relaxin ELISA. Statistical analysis was performed using Student’s t test. Results. Serum RLX appeared to be significantly higher (p < 0.001) in patients with SSc compared to controls. RLX appeared significantly increased (p < 0.001) in male patients compared to male controls, and in female patients compared to female controls. RLX was significantly higher (p <0.001) in female patients and female controls compared to male patients and male controls. Conclusion. In patients with SSc, the increased level of RLX represents a defensive response against the fibrotic process.